Search Results - subject:"Chronic obstructive"

Auswirkungen und Erfolgsfaktoren von Disease Management : Versorgungsansätze für chronisch kranke Patienten am Beispiel von Asthma und chronisch obstruktiven Lungenerkrankungen

Kranzer, Andrea - 2008

Persistent link: https://www.econbiz.de/10004910084

Auswirkungen und Erfolgsfaktoren von Disease Management : Versorgungsansätze für chronisch kranke Patienten am Beispiel von Asthma und chronisch obstruktiven Lungenerkrankungen

Kranzer, Andrea (contributor) - 2008

Schlüsselprobleme in der Leistungserbringung vor der Einführung der Reformansätze -- Reformansätze zur Verbesserung der medizinischen Versorgung -- Darstellung von Disease Management -- Disease-Management-Projekte für Asthma und COPD in Deutschland -- Empirische Evaluation des Projekts...

Persistent link: https://www.econbiz.de/10013516778

Systematic review on inhaled corticosteroid monotherapy and its efficacy and safety in longterm treatment of patients with chronic obstructive pulmonary disease (COPD)

Buchberger, Barbara; Niebuhr, Dea; Kossmann, Beate; … - 2011

Persistent link: https://www.econbiz.de/10010307917

Systematic review on inhaled corticosteroid monotherapy and its efficacy and safety in longterm treatment of patients with chronic obstructive pulmonary disease (COPD)

Buchberger, Barbara; Niebuhr, Dea; Kossmann, Beate; … - Fachbereich Wirtschaftswissenschaften, Universität … - 2011

Persistent link: https://www.econbiz.de/10009647193

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

Samyshkin, Yevgeniy; Kotchie, Robert; Mörk, Ann-Christin; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 69-82

The addition of roflumilast to LABA in the treatment of patients with severe-to-very severe COPD reduces the rate of exacerbations and can be cost-effective in the UK setting. </AbstractSection> Copyright The Author(s) 2014

Persistent link: https://www.econbiz.de/10010993843

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

Samyshkin, Yevgeniy; Kotchie, Robert W.; Mörk, Ann-Christin - In: The European journal of health economics : HEPAC ; … 15 (2014) 1, pp. 69-82

Persistent link: https://www.econbiz.de/10010235895

Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease: A Review of the Evidence and Methodological Issues

Rutten-van Molken, Maureen P.M.H. Rutten-van Mlken; … - In: PharmacoEconomics 30 (2012) 4, pp. 271-302

Background:Background: Over 200 million people have chronic obstructive pulmonary disease (COPD) worldwide. The number …

Persistent link: https://www.econbiz.de/10009653280

A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease

Menn, Petra; Leidl, Reiner; Holle, Rolf - In: PharmacoEconomics 30 (2012) 9, pp. 825-840

Background:Background: Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death … GOLD [Global Initiative for Chronic Obstructive Lung Disease] classification, states after lung-volume reduction …

Persistent link: https://www.econbiz.de/10010561838

New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses

Mapel, Douglas W.; Roberts, Melissa H. - In: PharmacoEconomics 30 (2012) 10, pp. 869-885

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability worldwide, but before …

Persistent link: https://www.econbiz.de/10010569819

Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease: Australia...

Mittmann, Nicole; Hernandez, Paul; Mellstrom, Carl Mellstrm - In: PharmacoEconomics 29 (2011) 5, pp. 403-414

Background: Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease associated with …

Persistent link: https://www.econbiz.de/10010614300